This year’s AAPS PharmSci 360 highlighted AI transparency, computer modeling in formulation, oral peptide delivery, and new business models.
|Articles|January 15, 2003
- BioPharm International-01-01-2003
- Volume 16
- Issue 1
Rethinking the Economics of Chromatography: New Technologies and Hidden Costs
Author(s)Tim N. Warner, Sam Nuchumson
by Tim N. Warner and Sam Nuchumson, Pall Life Sciences If the hidden expenses associated with laboratory purchases ? labor, cleaning, buffers, validation, time delays ? are identified, reduced processing costs, higher throughput, and accelerated time-to-market are possible. This comparison between resin and membrane chromatography helps shed light on some hidden costs.
Advertisement
Articles in this issue
almost 24 years ago
Biotech World: Canada's Supreme Court says "No" to Harvard Mousealmost 24 years ago
Guest Editorial: At the Governance Crossroadalmost 24 years ago
Reducing Costs by Facility Designalmost 24 years ago
Guidelines for Optimization and Scale-Up in Preparative Chromatographyalmost 24 years ago
Survival Strategies: Board Compensation Changing with the TimesAdvertisement
Related to this article
FDA approves Sun Pharma’s Ilumya for active psoriatic arthritis, BioMarin licenses a subcutaneous Fabry enzyme replacement therapy from GC Biopharma and Hanmi, and Lonza expands bioconjugation capacity in Visp to meet rising ADC demand.
In the second part of an interview for BioPharm International’s AAPS PharmSci 360 2026 coverage, Nanoform’s Chris Worrall shares 18-month stability data for a 414 mg/mL trastuzumab suspension and explains how ultra-high-concentration formulations could shorten administration and support at-home injection.
Industry experts discuss how reshoring, fill/finish capacity, and cold chain technology are shaping a more resilient biopharma supply chain.
Lonza's Visp expansion adds 3 multiproduct suites at up to 1200 L plus 500-L single-use capacity to scale commercial ADC production from 2028.
The first-in-class molecule, licensed to Dianthus as DNTH212 outside Greater China, is designed to block type 1 interferon production and BAFF/APRIL-driven B-cell activity with a single drug.
HM15421/GC1134A could become the first subcutaneous enzyme replacement therapy for Fabry disease, with BioMarin paying $70 million upfront.
The IL-23p19 inhibitor tildrakizumab becomes the third drug in its class approved for psoriatic arthritis, and the only one given exclusively by a healthcare provider.
Advertisement
Advertisement
Trending on BioPharm International
1
Lonza Adds Bioconjugation Suites in Visp to Meet Rising ADC Demand
2
AAPS 2026 PharmSci 360 Video Recap: AI Transparency, Oral Peptides, and New Models
3
The BioPharm Brief: A Psoriatic Arthritis Approval, a Subcutaneous Fabry Bet, and ADC Capacity
4
Drug Digest: Reshoring Manufacturing and Securing Cold-Chain Supply for Biopharma
5